FDA Approves Dabrafenib and Trametinib Combination for Metastatic NSCLC with BRAF V600E Mutation
On June 22, 2017, the U.S. Food and Drug Administration granted (FDA) regular approvals to dabrafenib and trametinib (Taflinar® and Mekinist®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
Combination Treatment Improves Survival for Advanced Melanoma
A combination of nivolumab and ipilimumab improved overall survival when compared to either drug alone, according to results from a recent study reported at the American Association for Cancer Research 2017 annual meeting.
Chemotherapy Plus Radiotherapy Not Superior to Radiotherapy Alone in Improving Survival for Patients With High-Risk Endometrial Cancer
Women with high-risk endometrial cancer (EC) are at an increased risk of metastasis and death. The randomized, intergroup PORTEC-3 study assessed the benefit of adjuvant chemotherapy during and after radiotherapy (RT) versus pelvic RT alone in this patient population. The researchers presented the study at the ASCO Annual Meeting.
The Challenge of Caring for Multiple Patients With Cancer
As more new treatments enter practice—like immunotherapy, targeted therapy, and combination therapies—oncology nurses are required to be experts in every treatment they administer. They need to constantly walk a tightrope, balancing multiple medications for one patient then quickly moving to the next patient on a completely different treatment protocol.
Bortezomib May Improve Outcomes in Multiple Myeloma
Adding bortezomib to combination therapy with lenalidomide and dexamethasone may improve progression-free and overall survival in patients with newly diagnosed multiple myeloma. The study findings were published in Lancet.
Combination Therapy Shows Promise for Chronic Myeloid Leukemia
According to the results of a new study published in Science Translational Medicine, a combination regimen consisting of a BCR-ABL tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor may one day result in a cure for chronic myeloid leukemia.